Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (19585)	4/25/1998 8:23:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Hi Andreas. I agree "As a long term investment being short the shares and long the warrants does not make any sense." Nevertheless, it might make sense for an arbitrageur such as Farallon, which I assume falls in the 'big boy' category. Big guys can short a stock and get the 'proceeds' from the sale. For example, assume F had 100 LGNDW. They could then short 100 LGND, have no net exposure to Ligand and get $1,412.50 to invest assuming they did it at the close on Friday. Arbs can invest at a lot higher rate than the interest rate implied by the premium ($1.1875 per share based on Friday's close) on the warrant. The warrant premium will decline to zero on the last exercise date so F will lose that as compared to selling the warrant now. But, the earnings an arb can generate on the $1,412.50 short proceeds should easily be 2 or 3 times that, again with essentially zero risk. Arbs are not in the business of taking risks, so I would be surprised if F has any material exposure to Ligand. I think they would just as soon liquidate their position, but it is too big and the warrant trading volume too low to sell much of it without taking a hair cut. The common stock trades more actively, thus facilitating the short sales. Regards, Walter